VYNE Therapeutics (VYNE) Total Debt (2019 - 2021)

VYNE Therapeutics' Total Debt history runs 3 years deep, the most recent figure standing at $33.4 million for Q2 2021.

• Quarterly Total Debt rose 1.4% year-over-year to $33.4 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $33.4 million (up 1.4% YoY) and the FY2020 annual result came in at $33.2 million, up 1.37% from the prior year.
• Total Debt was $33.4 million for Q2 2021 at VYNE Therapeutics, roughly flat from $33.3 million in the prior quarter.
• Across five years, Total Debt topped out at $52.5 million in Q1 2020 and bottomed at $32.7 million in Q4 2019.
• A 3-year average of $35.8 million and a median of $33.2 million in 2020 frame the typical range for Total Debt.
• Peak annual rise in Total Debt reached 1.4% in 2021, while the deepest fall reached 36.57% in 2021.
• VYNE Therapeutics' Total Debt stood at $32.7 million in 2019, then advanced by 1.37% to $33.2 million in 2020, then rose by 0.61% to $33.4 million in 2021.
• Business Quant data shows VYNE's Total Debt at $33.4 million in Q2 2021, $33.3 million in Q1 2021, and $33.2 million in Q4 2020.